Your Global Leader in Stem Cell Market Research
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and diverse market for iPSC research tools has emerged. Included below is a ten-year history of iPSC grants (source: RePORT.NIH.gov), clinical trials (source: ClinicalTrials.gov), and scientific publications (source: PubMed.gov).
Both graphs below reveal the iPSC market is expanding. [Read more…]
Pompano Beach, FL, March 13, 2018 — BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a focus in Pharmaceuticals and Regenerative Medicine, announced today the addition of Dr. Felix Amon, who will consult BSEM with Pharmaceutical Business Development.
[Read more…]
Passed December 13, 2016, the 21st Century Cures Act authorizes $6.3 billion in funding. It will support the development of innovative regenerative medicines, by providing substantial funding to the U.S. NIH and the FDA, among other groups.
In this article:
MELBOURNE, Australia, Feb. 27, 2018 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the Primary Evaluation Period has been completed for the first cohort of patients in the clinical trial of its lead Cymerus™ mesenchymal stem cell (MSC) product CYP-001, for the treatment of steroid-resistant graft versus host disease (GvHD). [Read more…]
